News World Hydroxychloroquine combination risky for cancer patients with COVID-19 -study

Hydroxychloroquine combination risky for cancer patients with COVID-19 -study

 

Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on Thursday.

The preliminary results suggest doctors may want to refrain from prescribing the decades-old malaria treatment hydroxychloroquine with the antibiotic azithromycin for these patients until more study is done, researchers said.

“Treatment with hydroxychloroquine and azithromycin were strongly associated with increased risk of death,” Dr. Howard Burris, president of the American Society of Clinical Oncology(ASCO), said in a briefing with reporters on the results.

The drug combination initially was thought to help COVID-19 patients, but recent data has cast doubt on the regimen.

The preliminary findings, to be presented this week at ASCO’s virtual scientific meeting, show that the combination may pose a significant risk to cancer patients.

“Taking the combination gives a three times increased risk of dying within 30 days of any cause,” Dr. Jeremy Warner of Vanderbilt University Medical System told reporters.

Trump, who has often promoted hydroxychloroquine, in a March 21 tweet called the combination potentially “one of the biggest game changers in the history of medicine.”

That was based on a study of fewer than 40 patients in the International Journal of Antimicrobial Agents. More recent studies have shown little or no benefit and increased risks.

Warner and colleagues analyzed data on 925 patients with cancer who became infected with the coronavirus between March and April. Thirteen percent of the patients died within 30 days of their diagnosis.

Overall, patients whose cancers were actively progressing at the time of infection were five times more likely to die within 30 days than those who were in remission or had no current evidence of cancer.

In the trial, 180 patients were taking hydroxychloroquine in combination with azithromycin, and 90 were taking hydroxychloroquine alone.

The U.S. Food and Drug Administration has allowed healthcare providers to prescribe the drugs for COVID-19 through an emergency-use authorization, but has not approved the treatment.

The governments of France, Italy and Belgium moved on Wednesday to halt the use of hydroxychloroquine for COVID-19 patients following a World Health Organization decision on Monday to pause a large trial of the drug due to safety concerns.

Warner said hydroxychloroquine alone was not a significant risk factor when adjusting for other risks, noting that the number of individuals taking the drug alone was relatively small.

He said carefully designed trials are needed to clarify the risks and benefits of these drugs alone or in combination.

Nevertheless, Warner said his findings were largely consistent with a retrospective analysis published last week in the Lancet medical journal that looked at more than 96,000 people hospitalized with COVID-19. That study found that hydroxychloroquine was associated with an increased risk of death and heart rhythm problems.

ASCO Chief Medical Officer Dr. Richard Schilsky said there is “insufficient evidence to support the routine use of hydroxychloroquine” to treat COVID-19 in patients who also have cancer, and urged caution until more data becomes available.

Schilsky said the treatment should only be used in the context of a clinical trial, per FDA guidance. Only two of the patients in the study were taking the drug as part of a clinical trial.

“This certainly will put a degree of caution for combining those two drugs in a cancer patient receiving therapy against COVID-19,” said Dr. William Cance, chief scientific officer of the American Cancer Society.

(Reuters)

Top Stories

Households and businesses affected by Medicane Ianos to be compensated

Prime Minister Kyriakos Mitsotakis promised the flood-stricken households and businesses of Karditsa that the government will stand at their side with "speed and determination",...

Workshop on forging synergies between industry and scientific research organised for Industry Week

A workshop was organised on Tuesday, in Nicosia, to discuss ways to forge synergies between industrial production and scientific research sectors, in a bid...

Cyprus-France Defence Ministers discuss East Med situation

Cyprus' Defence Minister Charalambos Petrides spoke on the phone with his French counterpart Florence Parly, on Tuesday, and according to Cyprus' Ministry of Defence...

Technical error causes Hezbollah arms depot to blow up in Lebanon, security source says

An arms cache belonging to the Iran-backed Lebanese group Hezbollah blew up in southern Lebanon on Tuesday because of a technical error, a security...

Turkey – Greece ready to resume exploratory talks, Erdogan says

Turkey and Greece stated they are ready to resume exploratory talks to address their contested maritime claims in the eastern Mediterranean and Aegean, the...

Taste

Souvlakia

Pork souvlaki: Put the meat and all the other ingredients in a bowl (not metal) and mix well. Cover the bowl and keep in...

Pastelli (Carob Toffee)

The nutritional sweet of Pastelli is made with the syrup of carob pods, produced by boiling their pulp until it forms a thick, sticky...

Meatballs with tomato and cumin

Place all meatball ingredients in a bowl and knead well with hands. Keep the mixture in the fridge for approximately 1 hour to thicken. In...

Crushed wheat pilaf with sausages and halloumi

Ingredients: 1 cup bulgar wheat ¼ of the cup vermicelli noodles or spaghetti, broken into small pieces 1 onion 2 sausages 1 cup tomato juice 1 vegetable stock cube 1/3 ts...